(12) PATENT APPLICATION PUBLICATION (21) Application No.5529/DELNP/2013 A (19) INDIA (22) Date of filing of Application :20/06/2013 (43) Publication Date : 05/12/2014 (54) Title of the invention: FUSED AMINODIHYDROTHIAZINE DERIVATIVES classification (51) International :A61K31/542,C07D279/08,C07D513/04(71)Name of Applicant: 1)EISAI R&D MANAGEMENT CO. LTD No (31) Priority Document : 1100181.5 Tokyo 112 8088 Japan Address of Applicant :6 10 Koishikawa 4 chome Bunkyo ku (32) Priority Date :06/01/2011 (72)Name of Inventor : country (33) Name of priority :U.K. 2)HALL Adrian l)DIMOPOULOS Paschalis Application No (86) International Filing Date PCT/EP2012/050122 05/01/901? 3)Κ1ΤΑ Yoichi 4)MADIN Andrew 5)SHUKER Nicola Louise Publication No (87) International :WO 2012/093148 Application Number (61) Patent of Addition to Filing Date :ΝΑ :ΝΑ Application Number (62) Divisional to Filing Date :ΝΑ :ΝΑ (57) Abstract: The present invention relates to a fused aminodihydrothiazine derivative of fonnula (I): wherein R is hydrogen or C alkyl optionally substituted by one to five halogen atoms; η is 0 1 2 or 3; Ar is phenyl or a 5 or 6 membered heteroaromatic group containing 1 2 or 3 Ν atoms which Ar is optionally substituted by one to three substituents selected from hal hydroxyl CN Calkyl Calkenyl Calkynyl alkoxy Ccycloalkoxy and pyrazine where Calkyl and Calkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by A and typified by Alzheimer type dementia. No. of Pages : 75 No. of Claims : 15 The Patent Office Journal 05/12/2014 12979 PCT/EP2012/050122or a pharmaceutically acceptable salt thereof.8. A compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in therapy.9. A compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for inhibiting beta-site amyloid-P precursor protein cleaving enzyme 1 (BACE1).10. A compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for treating a neurodegenerative disease such as Alzheimer-type dementia or Down’s syndrome.11. Use of a compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a neurodegenerative disease such as Alzheimer-type dementia or Down's syndrome.12. A compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for treating type 2 diabetes.13. Use of a compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of type 2 diabetes.14. A pharmaceutical composition comprising the compound as claimed in any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, as an active ingredient in association with a pharmaceutically acceptable carrier.15. A pharmaceutical product comprising, in combination, a first active ingredient which is a compound as claimed in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, and at least one further active ingredient useful in treating a neurodegenerative disease.this 20/06/2013(ΝΕΗΑ SRIVASTAVA) OF REMFRY & SAGAR ATTORNEY FOR THE APPLICANTS]